Bayforest Capital Ltd Sells 4,061 Shares of Jazz Pharmaceuticals PLC $JAZZ

Bayforest Capital Ltd trimmed its stake in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 70.1% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,730 shares of the specialty pharmaceutical company’s stock after selling 4,061 shares during the period. Bayforest Capital Ltd’s holdings in Jazz Pharmaceuticals were worth $228,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Royal Bank of Canada raised its stake in Jazz Pharmaceuticals by 96.5% during the 1st quarter. Royal Bank of Canada now owns 67,614 shares of the specialty pharmaceutical company’s stock valued at $8,394,000 after buying an additional 33,210 shares during the last quarter. Goldman Sachs Group Inc. grew its holdings in shares of Jazz Pharmaceuticals by 147.7% in the first quarter. Goldman Sachs Group Inc. now owns 351,609 shares of the specialty pharmaceutical company’s stock worth $43,652,000 after acquiring an additional 209,667 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in Jazz Pharmaceuticals by 4.2% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 197,174 shares of the specialty pharmaceutical company’s stock valued at $24,479,000 after acquiring an additional 7,954 shares during the last quarter. Focus Partners Wealth lifted its holdings in Jazz Pharmaceuticals by 3.4% in the first quarter. Focus Partners Wealth now owns 4,623 shares of the specialty pharmaceutical company’s stock valued at $574,000 after acquiring an additional 154 shares during the period. Finally, Geneos Wealth Management Inc. grew its stake in shares of Jazz Pharmaceuticals by 57.6% during the 1st quarter. Geneos Wealth Management Inc. now owns 375 shares of the specialty pharmaceutical company’s stock valued at $47,000 after purchasing an additional 137 shares during the period. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on JAZZ. Bank of America increased their price objective on shares of Jazz Pharmaceuticals from $230.00 to $247.00 and gave the stock a “buy” rating in a research note on Tuesday, November 18th. Morgan Stanley reiterated an “overweight” rating and set a $225.00 price target on shares of Jazz Pharmaceuticals in a research note on Thursday, January 8th. Piper Sandler restated an “overweight” rating and issued a $219.00 price objective (up from $147.00) on shares of Jazz Pharmaceuticals in a research note on Wednesday, December 10th. Royal Bank Of Canada set a $194.00 target price on Jazz Pharmaceuticals and gave the stock an “outperform” rating in a report on Monday, November 17th. Finally, UBS Group reissued a “neutral” rating and set a $188.00 price target (up previously from $163.00) on shares of Jazz Pharmaceuticals in a report on Monday, November 24th. Thirteen investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Jazz Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $205.67.

Insider Activity at Jazz Pharmaceuticals

In related news, Director Bruce C. Cozadd sold 77,500 shares of the business’s stock in a transaction that occurred on Wednesday, November 26th. The stock was sold at an average price of $177.81, for a total value of $13,780,275.00. Following the transaction, the director directly owned 393,332 shares of the company’s stock, valued at approximately $69,938,362.92. The trade was a 16.46% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Rick E. Winningham sold 5,500 shares of the stock in a transaction that occurred on Tuesday, November 18th. The shares were sold at an average price of $180.86, for a total transaction of $994,730.00. Following the sale, the director directly owned 8,893 shares of the company’s stock, valued at approximately $1,608,387.98. This trade represents a 38.21% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 123,791 shares of company stock worth $21,991,850 in the last three months. Corporate insiders own 4.30% of the company’s stock.

Jazz Pharmaceuticals Price Performance

NASDAQ:JAZZ opened at $162.43 on Wednesday. The business’s 50-day simple moving average is $164.83 and its two-hundred day simple moving average is $138.64. Jazz Pharmaceuticals PLC has a 52 week low of $95.49 and a 52 week high of $182.99. The stock has a market cap of $9.87 billion, a PE ratio of -26.76, a P/E/G ratio of 0.75 and a beta of 0.27. The company has a quick ratio of 1.44, a current ratio of 1.65 and a debt-to-equity ratio of 1.09.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.